$1.14 Billion is the total value of Casdin Capital, LLC's 41 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 29.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BLFS | Buy | BIOLIFE SOLUTIONS INC | $170,645,924 | +3.6% | 7,721,535 | +2.0% | 14.91% | +9.9% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $116,237,800 | -27.3% | 1,015,000 | -12.5% | 10.16% | -22.9% |
| RLAY | Buy | RELAY THERAPEUTICS INC | $75,342,089 | -19.7% | 5,998,574 | +5.3% | 6.58% | -14.8% |
| EQRX INC | $73,521,464 | -4.1% | 39,527,669 | 0.0% | 6.42% | +1.7% | ||
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $53,183,200 | -1.7% | 280,000 | +3.7% | 4.65% | +4.3% |
| NTLA | INTELLIA THERAPEUTICS INC | $51,994,500 | +9.4% | 1,275,000 | 0.0% | 4.54% | +16.1% | |
| RVMD | REVOLUTION MEDICINES INC | $48,417,500 | +23.5% | 1,810,000 | 0.0% | 4.23% | +31.0% | |
| EXAS | Sell | EXACT SCIENCES CORP | $46,950,000 | +22.5% | 500,000 | -11.5% | 4.10% | +30.0% |
| VERV | Buy | VERVE THERAPEUTICS INC | $44,260,706 | +44.7% | 2,360,571 | +11.3% | 3.87% | +53.6% |
| Buy | STRUCTURE THERAPEUTICS INCsponsored ads | $41,445,997 | +157.3% | 997,017 | +47.3% | 3.62% | +172.9% | |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $39,184,000 | +30.0% | 620,000 | -7.5% | 3.42% | +37.9% |
| DNLI | DENALI THERAPEUTICS INC | $38,363,000 | +28.1% | 1,300,000 | 0.0% | 3.35% | +35.9% | |
| Buy | TENAYA THERAPEUTICS INC | $37,458,683 | +116.2% | 6,381,377 | +5.0% | 3.27% | +129.4% | |
| CTLT | New | CATALENT INC | $31,219,200 | – | 720,000 | +100.0% | 2.73% | – |
| PLRX | Buy | PLIANT THERAPEUTICS INC | $30,804,000 | -30.9% | 1,700,000 | +1.5% | 2.69% | -26.6% |
| SOMALOGIC INC | $29,115,875 | -9.4% | 12,604,275 | 0.0% | 2.54% | -3.9% | ||
| ILMN | Sell | ILLUMINA INC | $29,060,950 | -54.6% | 155,000 | -43.6% | 2.54% | -51.8% |
| Sell | MAXCYTE INC | $21,641,850 | -11.2% | 4,715,000 | -4.3% | 1.89% | -5.8% | |
| 2SEVENTY BIO INC | $20,482,000 | -0.8% | 2,023,913 | 0.0% | 1.79% | +5.3% | ||
| FDMT | 4D MOLECULAR THERAPEUTICS IN | $19,334,900 | +5.1% | 1,070,000 | 0.0% | 1.69% | +11.6% | |
| New | GENEDX HOLDINGS CORP | $18,449,246 | – | 3,095,511 | +100.0% | 1.61% | – | |
| BEAM | BEAM THERAPEUTICS INC | $18,200,100 | +4.3% | 570,000 | 0.0% | 1.59% | +10.6% | |
| ABCL | ABCELLERA BIOLOGICS INC | $16,279,200 | -14.3% | 2,520,000 | 0.0% | 1.42% | -9.1% | |
| IPSC | CENTURY THERAPEUTICS INC | $10,132,161 | -8.9% | 3,206,380 | 0.0% | 0.88% | -3.4% | |
| FATE | FATE THERAPEUTICS INC | $9,758,000 | -16.5% | 2,050,000 | 0.0% | 0.85% | -11.4% | |
| RNA | AVIDITY BIOSCIENCES INC | $9,426,500 | -27.8% | 850,000 | 0.0% | 0.82% | -23.3% | |
| TWST | Sell | TWIST BIOSCIENCE CORP | $9,207,000 | -12.8% | 450,000 | -35.7% | 0.80% | -7.5% |
| Sell | PRIME MEDICINE INC | $5,379,114 | -40.4% | 367,175 | -50.0% | 0.47% | -36.8% | |
| INCY | INCYTE CORP | $4,824,375 | -13.9% | 77,500 | 0.0% | 0.42% | -8.5% | |
| SANA | New | SANA BIOTECHNOLOGY INC | $4,470,000 | – | 750,000 | +100.0% | 0.39% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $4,231,800 | – | 90,000 | +100.0% | 0.37% | – |
| GLUE | MONTE ROSA THERAPEUTICS INC | $3,499,542 | -12.1% | 510,882 | 0.0% | 0.31% | -6.7% | |
| TANGO THERAPEUTICS INC | $3,320,000 | -15.9% | 1,000,000 | 0.0% | 0.29% | -10.8% | ||
| FLDM | New | STANDARD BIOTOOLS INC | $2,316,000 | – | 1,200,000 | +100.0% | 0.20% | – |
| Sell | ABSCI CORPORATION | $2,079,755 | -78.0% | 1,368,260 | -74.6% | 0.18% | -76.6% | |
| EXSCIENTIA PLCads | $1,266,288 | +11.7% | 213,900 | 0.0% | 0.11% | +19.4% | ||
| OMIC | SINGULAR GENOMICS SYSTEMS IN | $1,116,949 | -31.4% | 1,345,722 | 0.0% | 0.10% | -26.9% | |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $860,400 | -95.5% | 23,814 | -95.3% | 0.08% | -95.2% |
| LIANBIOsponsored ads | $470,626 | +16.9% | 206,415 | 0.0% | 0.04% | +24.2% | ||
| KRON | KRONOS BIO INC | $213,003 | +17.8% | 123,839 | 0.0% | 0.02% | +26.7% | |
| New | SCILEX HOLDING CO | $130,962 | – | 23,512 | +100.0% | 0.01% | – | |
| NVTA | Exit | INVITAE CORP | $0 | – | -1,038,388 | -100.0% | -0.12% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INCcall | $0 | – | -25,000 | -100.0% | -0.28% | – |
| OPRX | Exit | OPTIMIZERX CORP | $0 | – | -500,000 | -100.0% | -0.60% | – |
| Exit | DICE THERAPEUTICS INC | $0 | – | -310,000 | -100.0% | -0.73% | – | |
| RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -150,000 | -100.0% | -1.33% | – |
| Exit | GENEDX HOLDINGS CORP | $0 | – | -102,151,785 | -100.0% | -3.07% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.